| Icotrokinra | A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | Phase 3 | Active not recruiting | 813 | Feb 10, 2027 |
| Guselkumab Subcutaneous | A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | Phase 3 | Active not recruiting | 112 | Feb 10, 2027 |
| IMAAVY | Nipocalimab in Moderate to Severe Sjogren's Disease | Phase 3 | Active not recruiting | 655 | Feb 4, 2027 |
| RYBREVANT FASPRO | A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | 71 | Jan 31, 2027 |
| Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Phase 3 | Active not recruiting | 539 | Dec 31, 2026 |
| Cetrelimab | A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Phase 3 | Active not recruiting | 518 | Dec 30, 2026 |
| JNJ-64042056 | A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | Phase 2 | Active not recruiting | 55 | Dec 22, 2026 |
| Milvexian | A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | Phase 3 | Active not recruiting | 20,284 | Dec 8, 2026 |
| ERLEADA | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | Phase 3 | Active not recruiting | 2,517 | Dec 1, 2026 |
| CARVYKTI | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma | Phase 2 | Active not recruiting | 11 | Aug 31, 2026 |
| EDURANT | A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies | Phase 2 | Completed | 48 | Aug 18, 2026 |
| DARZALEX | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | Phase 2 | Active not recruiting | 210 | Aug 4, 2026 |
| ERLEADA | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | Phase 3 | Active not recruiting | 1,503 | Jun 30, 2026 |
| JNJ-89495120 | A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Completed | 107 | Jun 25, 2026 |
| RYBREVANT FASPRO | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | 57 | Jun 9, 2026 |
| SPRAVATO | Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy | Phase 2 | Completed | 118 | Jun 1, 2026 |
| DARZALEX | Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | Phase 2 | Active not recruiting | 73 | May 31, 2026 |
| Ustekinumab | An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study | Phase 3 | Completed | 41 | May 29, 2026 |
| RYBREVANT FASPRO | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer | Phase 2 | Completed | 12 | May 14, 2026 |
| TECVAYLI | A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Completed | 40 | Apr 13, 2026 |
| Macitentan Tablets | Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH | Phase 3 | Terminated | 7 | Mar 26, 2026 |
| Dupilumab | A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) | Phase 2 | Terminated | 256 | Mar 26, 2026 |
| Metformin | ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging | Phase 2 | Completed | 31 | Feb 25, 2026 |
| JNJ-81201887 | A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Phase 2 | Completed | 305 | Feb 23, 2026 |
| Ad26.Mos4.HIV | Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults | Phase 2 | Completed | 28 | Feb 23, 2026 |
| Milvexian | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome | Phase 3 | Completed | 14,194 | Feb 6, 2026 |
| Erdafitinib | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | Terminated | 11 | Feb 2, 2026 |
| Risperidone 4mg/day | Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone | Phase 2 | Completed | 80 | Jan 30, 2026 |
| ERLEADA | AASUR in High Risk Prostate Cancer | Phase 2 | Completed · results | 64 | Jan 22, 2026 |
| TREMFYA | A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis | Phase 3 | Completed | 48 | Jan 12, 2026 |
| Niraparib | Niraparib in Patients With Pancreatic Cancer | Phase 2 | Completed | 32 | Dec 31, 2025 |
| Daratumumab and Hyaluronidase-fihj | Daratumumab in STK11 Mutated NSCLC | Phase 2 | Completed | 8 | Nov 11, 2025 |
| JNJ-63733657 | A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | Phase 2 | Terminated · results | 523 | Oct 17, 2025 |
| Lazertinib | Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | Phase 2 | Terminated | 14 | Oct 10, 2025 |
| DARZALEX | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | Phase 2 | Terminated · results | 13 | Oct 9, 2025 |
| IMAAVY | A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies | Phase 2 | Completed | 36 | Sep 4, 2025 |
| ExPEC9V | A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | Phase 3 | Completed · results | 17,797 | Aug 27, 2025 |
| XARELTO | RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome | Phase 2 | Completed | 43 | Jul 31, 2025 |
| ERLEADA | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | Phase 2 | Terminated · results | 8 | Jul 29, 2025 |
| PIPE-307 Dose A | Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis | Phase 2 | Completed | 182 | Jul 14, 2025 |